Sci-B-Vac®

The only commercially-available trivalent vaccine containing pre-S1, pre-S2, and S antigens of Hepatitis B

Sci-B-Vac® Overview

Sci-B-Vac® is a licensed, third-generation hepatitis B vaccine that has demonstrated safety and efficacy in over 500,000 patients. Sci-B-Vac® is currently approved for use in Israel and 10 other countries. In December 2017, VBI initiated patient dosing in a global, 15-month Phase 3 clinical program that, if successful, will allow the company to seek marketing authorization in the U.S., Europe, and Canada.

Sci-B-Vac® Highlights
  • Mimics all three surface antigens of the hepatitis B virus (“HBV”)
  • Offers high levels of anti-HBV antibodies
  • Offers rapid onset of protection
  • Can be administered at lower doses than competing hepatitis B vaccines
  • Free of next-generation adjuvants
Third-Generation Sci-B-Vac®
Second-Generation Hepatitis B Vaccine

Countries that have approved Sci-B-Vac®

Central African Republic, Chile, Côte d’Ivoire (Ivory Coast), Ethiopia, Gabon, Guinea Equatorial, Hong Kong, Israel, Niger, Nigeria, and Philippines.

Sci-B-Vac® is available as part of an Expanded Access Program (EAP) in certain jurisdictions. For more information about the Sci-B-Vac® EAP program, interested parties should contact Gloria Ferrer at gferrer@wepclinical.com.

About Hepatitis B
Vaccine Approaches
About Sci-B-Vac®
Development Plan

Hepatitis B Unmet Need: Low Vaccination Rates

Hepatitis B is a disease of the liver caused by the hepatitis B virus (“HBV”), characterized by liver inflammation, injury, and even cell death. The disease can present acutely, and resolve on its own, or it can progress to a chronic state. Despite advances in currently available antiviral therapies, only a minority of patients with chronic hepatitis B will have a sustained immune response to treatment. Therefore, primary prevention by vaccination is considered the ideal way to control hepatitis B infection.

Hepatitis B vaccines have been available for more than two decades, but infection with HBV remains a worldwide health problem, largely due to low vaccination rates. In a 2015 surveillance study, the U.S. Centers for Disease Control and Prevention (“CDC”) found that hepatitis B vaccination coverage (defined as having received three or more doses of a hepatitis B vaccine) was only 25% among adults aged 19 and older, 32% among adults aged 19 to 49, and 17% among adults aged 50 and up.

In addition, while second-generation HBV vaccines are highly protective against hepatitis B in young individuals, as individuals age, the immune system’s capacity to elicit a protective response decreases. The likelihood of success decreases further if you consider other comorbidities such as diabetes and end-stage renal disease (“ESRD”). Given the aging U.S. population and the low rate of adult hepatitis B vaccination in the U.S., it is becoming increasingly important to develop a hepatitis B vaccine that can induce a more immunogenic response.

U.S. Hepatitis B Vaccination Coverage (≥ 3 doses)
Otherwise Healthy
     Adults Aged ≥ 19 years 24.6%
     Adults Aged 19-49 years 32.0%
     Adults Aged ≥ 50 years 16.5%
High-Risk
     Chronic Liver Conditions 27.4%
     Diabetics – Aged 19-59 years 24.4%
     Diabetics – Aged ≥ 60 years 12.6%
     Healthcare Providers ≥ 19 years 64.7%

2015 CDC Surveillance of Vaccination Coverage Among Adult Populations

Phase III Clinical Program

The ongoing Phase III clinical program seeks to support Sci-B-Vac licensure in the U.S., Europe, and Canada. VBI seeks to enroll ~4,500 adults age 18 years and older at ~40 sites across the U.S., Europe, and Canada. The two concurrent Phase III studies are PROTECT, a safety and immunogenicity study, and CONSTANT, a lot-to-lot consistency study.

PROTECT – Safety and Immunogenicity Study

PROTECT is a double-blind, two-arm, randomized, controlled study, that enrolled subjects 18 years of age and older. Subjects were randomized in a 1:1 ratio to receive either a three-dose course of Sci-B-Vac® 10 μg or a three-dose course of the control vaccine, Engerix-B® 20 μg. Under the planned dosing schedule, subjects were vaccinated at months zero, one, and six. Enrollment was stratified by age group.

The co-primary objectives of the PROTECT study are:

  • To demonstrate non-inferiority of the seroprotection rate induced by Sci-B-Vac® vs. Engerix-B® four weeks after the third vaccination in adults age 18 and older.
  • To demonstrate superiority of the seroprotection rate induced by Sci-B-Vac® vs. Engerix-B® four weeks after the third vaccination in adults older than 45 years of age.

The study also includes multiple secondary objectives to evaluate the speed to seroprotection, including assessment after two doses of Sci-B-Vac® vs. three doses of Engerix-B®, and the overall safety and tolerability of Sci-B-Vac® vs. Engerix-B®.

CONSTANT – Lot-to-Lot Consistency Study

CONSTANT is a double-blind, four-arm, randomized, controlled study. Approximately 3,200 adult subjects, age 18-45 years, will be randomized in a 1:1:1:1 ratio to receive one of four three-dose courses: Lot A of Sci-B-Vac 10μg, Lot B of Sci-B-Vac 10μg, Lot C of Sci-B-Vac 10μg, or the control vaccine Engerix-B® 20μg.

The primary objective of this study is:

  • To demonstrate lot-to-lot consistency for immune response as measured by geometric mean concentration (GMC) of antibodies across three independent, consecutive lots of Sci-B-Vac four weeks after the third vaccination.

The secondary objective will be to evaluate safety and efficacy of Sci-B-Vac vs. Engerix-B®.

Recent Sci-B-Vac® News and Insights